Please login to the form below

Not currently logged in
Email:
Password:

dabigatran

This page shows the latest dabigatran news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Lynparza in breast cancer, Dupixent in asthma

CHMP backs Lynparza in breast cancer, Dupixent in asthma

So far, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - is the only NOAC on the market with a reversal agent available.

Latest news

More from news
Approximately 9 fully matching, plus 69 partially matching documents found.

Latest Intelligence

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    American College of Cardiology (ACC) to educate cardiologists in China about stroke prevention in atrial fibrillation (AF) – a condition for which Boehringer markets Pradaxa (dabigatran).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Between March 2011 and February 2012, dabigatran etexilate sales crossed the 'blockbuster' $1bn threshold. ... Interestingly, a study published in Stroke in March 2012 found that dabigatran etexilate was a cost-effective alternative to warfarin.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics